Occam Places Steve Colletti as CSO of Korro Bio

Occam Places Steve Colletti as CSO of Korro Bio

Korro Bio is an RNA editing company focused on the discovery and development of a new class of precision genetic medicines for both rare and common diseases. The company has raised over $200M across two rounds of financing. Top-tier investors include Atlas, Qiming, Fidelity, Point72, NEA, Eventide, Cormorant Asset Management, and Citadel.

In Colletti, Korro captures an RNA domain expert and a broadly gauged scientific leader who speaks the languages of both chemistry and biology, a bifocal perspective that he has leveraged to great effect across discovery and translation through early clinical development. After a highly successful R&D career at Merck, Colletti effectively transitioned to Biotech with Lodo which was subsequently acquired by Zymergen.

About Occam Global

Occam Global is an executive recruiting and leadership advisory firm with specialties across technological fields including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.